CLDN4 and gastric cancer: In light of our discovery of elevated CLDN4 expression in GC using single‐cell transcriptomics, we devised a novel therapeutic agent termed NESC to specifically target CLDN4‐overexpressing GC cells, aiming to bolster the effectiveness of GC treatment.